Title:
ISOTOPICALLY LABELLED SELECTIVE CXCR4 BINDING PEPTIDE CONJUGATE AND METHODS FOR MAKING AND USING THE SAME
Document Type and Number:
WIPO Patent Application WO/2021/150258
Kind Code:
A9
Abstract:
The present invention provides a selective CXCR4 binding peptide conjugate ("PC"), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate ("PC") is of the formula: (SEQ ID NO:1) or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders. Compositions, kits and methods are also disclosed herein for such uses.
Inventors:
ZHANG JUNGE (US)
YAN LIANG (US)
YAN LIANG (US)
Application Number:
PCT/US2020/025522
Publication Date:
November 11, 2021
Filing Date:
March 27, 2020
Export Citation:
Assignee:
MAINLINE BIOSCIENCES LLC (US)
International Classes:
C07K7/06; C07K5/12; C07K7/50
Attorney, Agent or Firm:
CHA, Don, D. (US)
Download PDF: